Viomycin
Viocin (viomycin) is a protein pharmaceutical. Viomycin was first approved as Viocin sulfate on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
391 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 24 | 102 | 26 | 3 | 8 | 148 |
| Non-small-cell lung carcinoma | D002289 | 11 | 44 | 28 | 3 | 4 | 90 | ||
| Brain stem neoplasms | D020295 | EFO_1001767 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | C34.90 | 6 | 22 | 18 | — | 2 | 44 | |
| Neoplasms | D009369 | C80 | 15 | 10 | 3 | — | 1 | 22 | |
| Hodgkin disease | D006689 | C81 | 1 | 10 | 2 | — | — | 13 | |
| Triple negative breast neoplasms | D064726 | 1 | 7 | 3 | — | 1 | 12 | ||
| Lymphoma | D008223 | C85.9 | 3 | 8 | 1 | — | — | 10 | |
| Uterine cervical neoplasms | D002583 | 3 | 3 | 3 | — | — | 8 | ||
| Rhabdomyosarcoma | D012208 | 2 | 4 | 2 | — | — | 7 | ||
| Non-hodgkin lymphoma | D008228 | C85.9 | 2 | 4 | 1 | — | — | 7 | |
| Sarcoma | D012509 | 2 | 5 | 1 | — | — | 6 | ||
| Malignant mesothelioma | D000086002 | 1 | 3 | 2 | — | — | 6 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | C61 | 3 | 9 | — | — | — | 10 | |
| Small cell lung carcinoma | D055752 | 3 | 3 | — | — | — | 4 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 3 | — | — | — | 4 |
| Male breast neoplasms | D018567 | 2 | 1 | — | — | — | 3 | ||
| Large b-cell lymphoma diffuse | D016403 | C83.3 | — | 3 | — | — | — | 3 | |
| Leukemia | D007938 | C95 | 3 | 1 | — | — | — | 3 | |
| Multiple myeloma | D009101 | C90.0 | 1 | 2 | — | — | — | 3 | |
| Mesothelioma | D008654 | C45 | — | 3 | — | — | — | 3 | |
| Head and neck neoplasms | D006258 | 1 | 2 | — | — | — | 2 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | — | — | — | 2 |
Show 29 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometrial neoplasms | D016889 | EFO_0004230 | 2 | — | — | — | — | 2 | |
| Urinary bladder neoplasms | D001749 | C67 | 1 | — | — | — | — | 1 | |
| Vaginal neoplasms | D014625 | C52 | 1 | — | — | — | — | 1 | |
| Renal cell carcinoma | D002292 | 1 | — | — | — | — | 1 | ||
| Pheochromocytoma | D010673 | 1 | — | — | — | — | 1 | ||
| Neuroendocrine carcinoma | D018278 | 1 | — | — | — | — | 1 | ||
| Islet cell carcinoma | D018273 | C25.4 | 1 | — | — | — | — | 1 | |
| Medullary carcinoma | D018276 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VIOMYCIN |
| INN | viomycin |
| Description | Viomycin is a cyclic peptide antibiotic produced by the actinomycete Streptomyces puniceus, used in the treatment of tuberculosis. It has a role as an antitubercular agent. It is a peptide antibiotic and a heterodetic cyclic peptide. It is a conjugate base of a viomycin(3+). |
| Classification | Peptide |
| Drug class | antibiotics (Streptomyces strain) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NCCC[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@H]([C@H]2C[C@H](O)NC(N)=N2)NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O |
Identifiers
| PDB | — |
| CAS-ID | 32988-50-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3085436 |
| ChEBI ID | 15782 |
| PubChem CID | 135398671 |
| DrugBank | DB06827 |
| UNII ID | YVU35998K5 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,468 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more